AstraZeneca Plc has agreed to buy Alexion Pharmaceuticals Inc. for $39 billion in cash and stock, adding a specialist in the treatment of rare diseases and immunology to its portfolio of medications for cancer and other illnesses.
To read the entire story, you must be logged in.
Please log in now or register with us.
